Unknown

Dataset Information

0

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.


ABSTRACT:

Background

Stromal tumor infiltrating lymphocytes (TILs) density is an outcome predictor in triple-negative breast cancer (TNBC). Herein we asked whether TILs are related to coding mutation load and to the chemical class of the resulting mutated amino acids, i.e., charged, polar, and hydrophobic mutations.

Methods

We examined paraffin tumors from TNBC patients who had been treated with adjuvant chemotherapy mostly within clinical trials (training cohort, N = 133; validation, N = 190) for phenotype concordance; TILs density; mutation load and types.

Results

Concordance of TNBC phenotypes was 42.1% upon local / central, and 72% upon central / central pathology assessment. TILs were not associated with mutation load, type and class of mutated amino acids. Polar and charged mutation patterns differed between TP53 and PIK3CA (p<0.001). Hydrophobic mutations predicted for early relapse in patients with high nodal burden and <50% TILs tumors (training: HR 3.03, 95%CI 1.11-8.29, p = 0.031; validation: HR 2.90, 95%CI 0.97-8.70, p = 0.057), especially if compared to patients with >50% TILs tumors (training p = 0.003; validation p = 0.015).

Conclusions

TILs density is unrelated to mutation load in TNBC, which may be regarded as an unstable phenotype. If further validated, hydrophobic mutations along with TILs density may help identifying TNBC patients in higher risk for relapse.

SUBMITTER: Kotoula V 

PROVIDER: S-EPMC5042538 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Stromal tumor infiltrating lymphocytes (TILs) density is an outcome predictor in triple-negative breast cancer (TNBC). Herein we asked whether TILs are related to coding mutation load and to the chemical class of the resulting mutated amino acids, i.e., charged, polar, and hydrophobic mutations.<h4>Methods</h4>We examined paraffin tumors from TNBC patients who had been treated with adjuvant chemotherapy mostly within clinical trials (training cohort, N = 133; validation, N = 1  ...[more]

Similar Datasets

| S-EPMC8759789 | biostudies-literature
| S-EPMC6769726 | biostudies-literature
| S-EPMC7850533 | biostudies-literature
| S-EPMC4570119 | biostudies-literature
| S-EPMC3899750 | biostudies-literature
| S-EPMC5362507 | biostudies-literature
| S-EPMC5814205 | biostudies-literature
| S-EPMC5607562 | biostudies-literature
| S-EPMC4021514 | biostudies-literature
| S-EPMC6467753 | biostudies-literature